Assessing the correlation between patient and family reported outcome measures and multiple myeloma clinical parameters

评估患者和家属报告的结局指标与多发性骨髓瘤临床参数之间的相关性

阅读:2

Abstract

Multiple Myeloma (MM) is characterized by multifaceted symptoms stemming from the disease itself, treatment complications, and involvement of various organs. MM significantly impacts the lives of patients and caregivers. This study aims to assess Patient Reported Outcome Measures (PROMs) and Family Reported Outcome Measures (FROMs) alongside conventional evaluation tools. A quantitative, prospective, observational study was conducted involving active MM patients. Participants completed PROMs/FROM-16 questionnaires quarterly for 12 months. Spearman correlation analysis was employed to explore associations between PROMs/FROM-16 and disease evaluation parameters. Friedman's test and Wilcoxon's test compared mean PROMs/FROM-16 scores at study onset with the following months. A better disease evaluation correlated with improvements in reported disease symptoms or treatment side effects by patients and with a reduced burden reported by caregivers (FROM-16). Additionally, favorable results in calcium levels, renal insufficiency, anemia, and bone lesions (CRAB) were associated with higher PROMs scores and less impact on caregivers. Moreover, patient PROMs scores reflected caregiver challenges and their ability to cope with the patient's illness. Most of the domains in PROMs demonstrated improvement, especially- quality of life, disease symptoms, body image scale, and future perspective, which improved 6 points that were defined in previous studies as minimal important difference. Finally, the results of our study showed that the total FROM-16 score improved from a mean score of 14.95 to 10.86 between the third month of the study, compared to the sixth month of the study, i.e., higher than 4, the minimal important change as defined in a previous study. This study underscores the utility of PROMs/FROM-16 in evaluating patient status from their perspective, facilitating tailored treatment approaches. It emphasizes the necessity of further research into the caregiver's experience with MM.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。